HARROW HEALTH, INC. HROW Cash Flow

Harrow health, inc. (HROW)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
CASH FLOWS FROM OPERATING ACTIVITIES
Total net (loss) income including noncontrolling interests
-24,381	-125	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss) attributable to Harrow Health, Inc.
-	-	-	-	-	-	-	-	-10,492	-11,985	-15,316	-13,474	-19,597	-19,087	-18,109	-18,211	-17,302	-15,899	-13,520	-12,020	-10,886	-10,118	-9,255	-8,880	-8,502	-7,643	-7,214	-6,382	-5,469	-5,383	-4,202	-3,041	-1,900	-953	0	0	0
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization of property, plant and equipment
1,994	1,936	1,750	1,776	1,599	1,608	1,583	1,542	1,455	1,401	1,397	1,363	1,317	1,055	768	504	294	255	203	128	78	37	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Estimated fair value of contributed services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Gain on forgiveness of liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	60	60	60	60	0	0	0
Amortization of prepaid consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Depreciation and amortization of furniture and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5	4	3	3	2	2	1	0	0	0	0	0
Amortization of intangible assets
192	209	234	243	237	235	268	300	334	364	361	177	350	351	353	534	364	355	281	206	130	48	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on contingent acquisition obligation
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt issuance costs and discount
537	512	541	562	589	613	632	660	801	978	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-111	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt issuance costs and discount
-	-	-	-	-	-	-	-	-	-	-	-	-	970	935	737	543	281	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt extinguishment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-189	-1,195	-1,195	-1,195	-1,006	0	0	0	0
Paid-in-kind interest added to principal of note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	203	204	203	181	130	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment loss
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale and disposal of assets
-	-4,148	0	0	0	-	-	-	-	-354	-215	-173	-15	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based payment of consulting services
-	234	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash gain on contingent acquisition obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31	31	31	31	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	113	113	113	113	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest on notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	24	43	62	77	75	0	0	0
Stock-based compensation
1,609	1,789	1,944	2,207	2,448	2,486	2,628	2,685	2,744	2,943	2,949	3,065	3,559	3,673	4,113	4,305	3,847	3,441	2,981	2,579	2,585	2,615	2,759	3,083	3,412	3,134	2,981	2,756	2,448	2,156	1,545	927	241	192	0	0	0
Payments made on behalf of Company by related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Accounts receivable
-165	95	1,083	862	719	384	-894	-1,496	-1,562	-1,392	-377	934	2,093	2,081	2,301	1,343	507	360	234	99	-23	23	10	23	2	0	0	0	0	-	-	-	-	-	-	-	-
Inventories
2,405	2,271	723	436	348	-415	150	384	409	821	885	804	811	429	199	155	29	314	627	388	266	160	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid consulting costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Prepaid expenses and other current assets
-342	471	251	419	807	123	171	196	-124	-274	-343	247	146	152	551	53	441	545	349	111	184	132	-14	511	204	16	272	-294	-140	-46	-1	24	-1	45	0	0	0
Accounts payable and accrued expenses
847	1,342	1,933	2,310	2,417	2,365	2,002	1,425	88	346	364	-249	883	1,515	1,831	2,477	1,920	1,028	818	148	304	345	-97	-205	-160	-239	399	398	258	231	0	0	0	-	-	-	-
Accounts payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Accrued Phase 3 expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0
Accrued payroll and related liabilities
1,358	-166	185	-220	50	1,074	437	315	62	-429	-3	349	313	438	197	425	-185	453	311	123	587	342	443	335	107	320	255	170	82	18	-38	-46	-38	-9	0	0	0
Deferred revenue and customer deposits
-299	-62	-50	190	286	90	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue and customer deposits
-	-	-	-	-	-	-	-	-	-	-46	-18	-42	26	33	-47	33	63	18	72	4	-11	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2	1	0	-100	-100	-100	-80	20	0	0	0
NET CASH USED IN OPERATING ACTIVITIES
1,876	950	-738	-345	176	687	429	-2,118	-5,788	-8,803	-10,747	-12,432	-12,894	-11,215	-12,278	-10,764	-11,169	-11,143	-9,895	-9,295	-7,656	-7,057	-6,242	-5,585	-5,057	-4,438	-3,813	-3,346	-2,623	-1,900	-1,261	-622	-405	-291	0	0	0
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable
-	-	-	-	-	4	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds on sale and disposal of assets
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment on note receivable
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of restricted short-term investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-50	-50	0	0	0	0	-	-	-	-
Purchase of Park Compounding, net of cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,005	3,005	3,005	3,005	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Pharmacy Creations, LLC, net of cash and advances
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-636	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Investment in patent and trademark assets
307	369	431	501	474	435	351	263	262	252	251	260	262	252	241	320	241	185	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash advances to Pharmacy Creations, LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Purchases of property, plant and equipment
1,475	1,468	1,289	1,783	1,789	1,768	1,252	1,000	814	772	935	1,464	4,670	6,887	4,841	4,542	1,344	-995	786	367	192	174	101	29	28	20	10	5	2	15	15	15	14	0	0	0	0
NET CASH USED IN INVESTING ACTIVITIES
-1,782	-1,833	-1,716	-2,284	-2,259	-2,199	-1,596	-1,146	-1,009	-961	-876	-1,824	-5,082	-7,289	-7,996	-7,897	-4,520	-5,130	-4,341	-3,372	-3,892	-910	-837	-765	-69	-70	-60	-55	-52	-15	-15	-15	-14	0	0	0	0
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on finance lease obligations
560	743	923	729	709	691	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments on capital lease obligations
-	-	-	-	-	-	-	-	-	626	612	558	412	267	126	28	25	25	24	20	17	10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from public equity offering
-	-	-	-	-	-	-	-	-	2,940	2,940	2,940	2,941	11,088	11,088	11,088	11,088	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from private placement equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Cancelled common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-
Payments on Park deferred acquisition obligation
-	-	-	-	-	53	158	158	209	206	151	199	197	195	193	192	183	135	87	40	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Principal payments on note payable
-	750	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from note payable, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,265	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from convertible note payable, net of issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	2,772	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from ATM sales of common stock
-	-	-	-	-	642	1,604	1,765	1,246	1,124	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	10,052	9,710	13,653	21,557	11,504	0	0	0	-	-	-	-
Payment for settlement of shares in connection with reverse stock split
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-
Proceeds from issuance of notes payable to a related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	150	450	750	750	600	300	0	0	0
Proceeds received in connection with debt modification
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	50	50	50	50	0	0	0	0
Proceeds from issuance of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	100	100	100	100	0	0	0
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Preferred stock deemed dividend paid at conversion
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-200	-200	0	0	0	-	-	-	-
Cash advances to and from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	254	254	254	254	0	0	0
Cash advances from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	27	27	27	0	0	0
Repayment of advances from related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	281	281	281	281	0	0	0
Capital contributions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Net proceeds from exercise of warrants
-	-	-	0	0	-	-	-	-	-	-	-	-	-88	45	45	1,216	1,238	1,249	1,386	350	622	621	484	349	0	0	0	0	-	-	0	0	0	0	0	0
Payments for deferred offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET CASH USED IN FINANCING ACTIVITIES
-235	-1,006	-230	2,652	3,456	4,131	3,415	3,069	2,093	4,930	13,128	12,980	13,551	24,672	16,080	14,051	24,612	10,747	10,428	10,616	245	599	617	483	349	10,052	9,711	13,654	21,508	11,805	12,265	8,349	495	145	0	0	0
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
-141	-1,889	-2,684	23	1,373	2,619	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
-	-	-	-	-	-	-	-	-	-	1,505	-1,276	-4,425	6,168	-4,194	-4,610	8,923	-5,526	-3,808	-2,051	-11,303	-7,368	-6,463	-5,868	-4,777	5,543	5,836	10,253	18,832	9,889	10,988	7,711	75	-145	0	0	0
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
4,608	4,749	3,954	6,661	8,011	6,638	6,267	3,824	2,692	4,019	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
200	200	200	200	200	200	200	200	200	200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
-	-	-	-	-	4	4	13	11	9	9	0	0	9	9	9	9	1	1	1	1	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
1,908	1,967	2,637	2,144	2,081	2,097	1,504	1,648	1,598	1,543	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Right-of-use asset obtained in exchange for lease obligation
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in accrued property and equipment purchases
-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition of property, plant and equipment with finance lease obligations
-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,207	1,185	926	637	415	70	6	4	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	0	0	0	-	-	-	-
Fair value of embedded conversion feature recorded as debt discount and derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	2,322	2,322	2,322	2,322	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the embedded conversion feature derivative liability to additional paid-in capital upon closing of the public equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	2,646	2,646	2,646	2,646	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the LSAF warrant from additional paid-in capital to derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	675	675	675	675	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of the fair value of the LSAF warrant derivative liability to additional paid-in capital upon closing of the public equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	464	464	464	464	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock and fair value of deferred acquisition obligations related to the purchase of Park Compounding
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,016	1,016	1,016	966	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of stock and stock options for consulting services included in accounts payable and accrued expenses
-	-	-	-	-	-	0	0	0	-	0	0	0	23	23	23	23	39	39	39	39	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property, plant and equipment included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of and adjustment to common stock and warrants to consulting firms for prepaid consulting fees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Conversion of related party accounts payable into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	56	56	56	56	0	0	0	0
Conversion of notes payable and accrued interest into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	762	1,905	0	0	0	-	0	0	0
Forgiveness of notes payable and accrued interest to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Forgiveness of notes payable and accrued interest to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0
Conversion of advances to notes payable to shareholders
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	0	0	0	0
Accretion of preferred stock discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-100	0	-100	-100	0	-100	0	0	0
Related party acquisition of Phase 3 liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56	0	56	56	112	56	0	0	0
Conversion of preferred stock into common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1	0	0	0	-	-	-	-
Reclassification of deferred offering costs in connection with equity offering
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	596	596	596	596	0	0	0	0	-	-	-	-
Issuance of common stock for consulting services included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	139	0	0	0	-	-	-	-	-	-	-	-
Purchase of property, plant and equipment included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	81	1,397	1,552	2,423	1,275	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Eton Pharmaceuticals [Member]
Investment (loss) gain, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Investment gain from and equity in net loss
-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Surface Pharmaceuticals [Member]
Investment (loss) gain, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Melt Pharmaceuticals [Member]
Investment (loss) gain, net
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-